Site search

Clear filter
2863 results for '' found
HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopat
HELIOS-B: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopat
/
Hearts and Minds: A 3-arm Multicentre, Randomised, Double-Blind, Placebo-Controlled Study of Metformin and Atorvastatin for the Treatment of Depression and Medical Comorbidity (ACTRN1262300061162
Hearts and Minds: A 3-arm Multicentre, Randomised, Double-Blind, Placebo-Controlled Study of Metformin and Atorvastatin for the Treatment of Depression and Medical Comorbidity (ACTRN1262300061162
/
Efficacy and Safety of HB-1 for Panic Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (NCT05071430)
Efficacy and Safety of HB-1 for Panic Disorder: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (NCT05071430)
/
Evaluation of safety and performance of the Half Moon Transcatheter Mitral Valve Repair (TMVr) System in High Risk Patients with Severe Symptomatic Mitral Regurgitation. (ACTRN04343313)
/
HALEO - A phase 3, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of NTLA-2002 in participants with hereditary angioedema [HAE] (NCT06634420
HALEO - A phase 3, multinational, randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of NTLA-2002 in participants with hereditary angioedema [HAE] (NCT06634420
/
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis (HABOR) (NCT04910685)
A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study of BLU-263 in Indolent Systemic Mastocytosis (HABOR) (NCT04910685)
/
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced
A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced
/
GS-US-548-5916: A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma (NCT04854499)
GS-US-548-5916: A Phase 2 Study of Magrolimab Combination Therapy in Patients with Head and Neck Squamous Cell Carcinoma (NCT04854499)
/
A Phase 2 Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults (NCT05729568)
A Phase 2 Study of GS-5423 and GS-2872 in Combination With Capsid Inhibitor Lenacapavir in Virologically Suppressed Adults (NCT05729568)
/
A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (NCT05
A Phase 3, Open-Label, Randomized Study of Perioperative Dostarlimab Monotherapy versus Standard of Care in Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (NCT05
/
43 44 45 46 47